BEHAVIORAL HEALTH

MHT’s SmarTest AI® solution can provide benefits seen at the patient, provider, and medical director level.

20% of all patients taking a PHQ-9 will score 15+. Of those patients, 50% will say “yes” when asked if they would like to learn more about advanced treatment options, such as TMS, Spravato, & IV Ketamine.

Proof of Concept Trial

Identify high-risk patients and direct them to appropriate level of care.
- Add-on CPT codes
- Identify additional diagnosis codes
- Meet MIPS/Quality Metric requirements
SmarTest AI® integrates with your EMR to automate the entire screening process. Your practice determines all screening parameters.
If a patient qualifies, SmarTest AI® asks if they would like to learn more about advanced treatment options, such as TMS. With patient consent, that referral is automated to the designated staff member or TMS coordinator.

SmarTest AI® Automated Workflow:

When SmarTest AI® is integrated with your EMR and a patient schedules an appointment, SmarTest AI® receives that information - including the appointment type.
Based on customized screening parameters set by the medical director, SmarTest AI® determines which assessments the patient should receive prior to the appointment.
Assessments are sent by text, email, or clinic device; results are automatically uploaded to the patient’s chart with abnormal results flagged.
Send designated staff members real-time alerts and redirect patients upon assessment completion to a URL of your choice.
If a patient qualifies, SmarTest AI® asks if they would like to be contacted by a specialist. With patient consent, that referral is automated to the appropriate level of care.